LSD and Psilocybin Research in Australia: Current Evidence

Introduction

Since Australia’s Therapeutic Goods Administration (TGA) made the landmark decision to down-schedule psilocybin and MDMA for therapeutic use in July 2023, the nation has positioned itself as a global leader in psychedelic research and clinical application . As of 2026, the evidence base for LSD and psilocybin research in Australia continues to grow, with new clinical trials, safety data, and real-world outcomes shaping the future of mental health treatment.

This article reviews the current evidence on LSD and psilocybin in Australia, including therapeutic applications, safety profiles, and emerging research directions.

The Australian Regulatory Landscape

Australia remains the first country in the world to legally permit psychedelic-assisted therapy for specific mental health conditions outside of clinical trials . Under the current framework:

• Authorised Prescribers (psychiatrists) can prescribe psilocybin for treatment-resistant depression (TRD) and MDMA for post-traumatic stress disorder (PTSD) 

• Other psychedelic medicines, including LSD, are legally in use as off-label or unapproved medicines under strict regulatory oversight 

• As at September 2025, 87 patients had received MDMA-assisted therapy and 47 patients had received psilocybin-assisted therapy through the Authorised Prescriber scheme 

Importantly, zero serious adverse events (SAEs) were reported across this patient cohort, providing early real-world evidence of safety when treatments are delivered under appropriate clinical supervision .

Current Evidence for Psilocybin Research in Australia

Psilocybin for Treatment-Resistant Depression

The most substantial Australian evidence base exists for psilocybin in treatment-resistant depression. The TGA’s decision to approve psilocybin for TRD was informed by international clinical trials demonstrating significant effect sizes .

Key findings from Australian and international research:

Ongoing Australian Trials

Several significant Australian trials are advancing the evidence base:

• Cybin IRL Ltd Phase 3 trial: The Sunshine Coast’s Thompson Brain and Mind Healthcare is the only Queensland site for this global trial testing psilocybin for major depressive disorders 

• Monash University preclinical research: Dr. Claire Foldi’s team is investigating psilocybin’s effects on social behavior and inflammation in female mice modeling anorexia nervosa, revealing that metabolic and exercise context critically influences outcomes 

The Monash research is particularly significant, demonstrating that:

• Psilocybin’s effects on sociability depend on food restriction and exercise history

• Inflammatory markers (interleukin-6) show context-dependent changes post-psilocybin

• These findings suggest personalized approaches may be essential for eating disorder treatment 

LSD Research in Australia: Current Evidence

Therapeutic Applications

While psilocybin and MDMA have received the most regulatory attention, LSD research in Australia is also advancing. LSD is legally available as an off-label medicine for appropriate patients under authorised prescribers .

Current evidence suggests potential applications for:

• Treatment-resistant depression

• Anxiety disorders

• Cluster headache (international evidence) 

• End-of-life psychological distress

LSD Safety Data: 2000-2023

A comprehensive retrospective study by Darke et al. (2024) examined all LSD- and psilocybin-related deaths in Australia from 2000 to 2023, providing crucial safety data .

Key findings for LSD:

Key findings for psilocybin:

Interpreting the Safety Data

The Darke study provides critical context for LSD and psilocybin safety in Australia :

1. Deaths are rare: Only 43 cases over 24 years across both substances

2. Trauma is the primary risk: Most deaths resulted from accidents or self-harm while intoxicated, not direct toxicity

3. Pure toxicity deaths are extremely uncommon: Only one case attributed solely to LSD toxicity; zero for psilocybin

4. Polydrug use is common: In most cases, multiple substances were involved

5. Pre-existing pathology is uncommon: Organ damage was rarely found at autopsy

As Korthuis et al. (2024) note in their commentary on this research: “Expanded psychedelic access requires new safety monitoring systems” to ensure these low mortality rates persist as therapeutic use expands .

Microdosing Research: Recent Findings

MindBio Therapeutics Phase 2B Trial (2026)

A recent Australian study by Melbourne-based MindBio Therapeutics has challenged assumptions about LSD microdosing for depression .

The Phase 2B trial of 89 adults with major depressive disorder found:

• Patients receiving LSD microdoses (4-20μg) showed worse Montgomery-Åsberg Depression Rating Scale (MADRS) scores compared to placebo (caffeine)

• While well-being improvements were observed, they were not clinically significant

• This represents “the most vigorous placebo-controlled trial ever performed in microdosing” according to CEO Justin Hanka 

The researcher concluded: “It’s probably a nail in the coffin of using microdosing to treat clinical depression. It probably improves the way depressed people feel—just not enough to be clinically significant or statistically meaningful.” 

The Placebo Effect in Psychedelic Research

These findings align with earlier research by Olson et al. (2020), whose “Tripping on Nothing” study demonstrated that placebo effects can be stronger than expected in psychedelic research. Participants given placebo but told it was a psychedelic reported feeling drug effects—suggesting that environment and expectation significantly influence outcomes .